Lv4
800 积分 2024-05-13 加入
Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors
1天前
已完结
Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors
11天前
已完结
Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors
16天前
已关闭
Preclinical safety profile of RC88-ADC：a novel mesothelin-targeted antibody conjugated with Monomethyl auristatin E
23天前
已完结
PKPD Assessment of the Anti-CD20 Antibody Obinutuzumab in Cynomolgus Monkey is Feasible Despite Marked Anti-Drug Antibody Response in This Species
24天前
已完结
Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors
24天前
已完结
Re-Evaluating Antibody–Drug Conjugate Linker Stability: Assessment, Interpretation, and Clinical Translation
26天前
已完结
Re-Evaluating Antibody–Drug Conjugate Linker Stability: Assessment, Interpretation, and Clinical Translation
26天前
已完结
Unlocking the potential of T cell engagers in solid tumors
1个月前
已完结
Nectin-4 expression patterns and therapeutics in oncology
1个月前
已完结
皖公网安备34019202002308
